title: Patient characteristics associated with buprenorphine/naloxone treatment outcome for prescription opioid dependence: Results from a multisite study.
abstract: BACKGROUND
  Prescription opioid dependence is a growing problem, but little research exists on its treatment, including patient characteristics that predict treatment outcome.
  
  
  METHODS
  A secondary analysis of data from a large multisite, randomized clinical trial, the National Drug Abuse Treatment Clinical Trials Network Prescription Opioid Addiction Treatment Study (POATS) was undertaken to examine baseline patient characteristics (N=360) associated with success during 12-week buprenorphine/naloxone treatment for prescription opioid dependence. Baseline predictor variables included self-reported demographic and opioid use history information, diagnoses assessed via the Composite International Diagnostic Interview, and historical opioid use and related information from the Pain And Opiate Analgesic Use History.
  
  
  RESULTS
  In bivariate analyses, pre-treatment characteristics associated with successful opioid use outcome included older age, past-year or lifetime diagnosis of major depressive disorder, initially obtaining opioids with a medical prescription to relieve pain, having only used opioids by swallowing or sublingual administration, never having used heroin, using an opioid other than extended-release oxycodone most frequently, and no prior opioid dependence treatment. In multivariate analysis, age, lifetime major depressive disorder, having only used opioids by swallowing or sublingual administration, and receiving no prior opioid dependence treatment remained as significant predictors of successful outcome.
  
  
  CONCLUSIONS
  This is the first study to examine characteristics associated with treatment outcome in patients dependent exclusively on prescription opioids. Characteristics associated with successful outcome after 12 weeks of buprenorphine/naloxone treatment include some that have previously been found to predict heroin-dependent patients' response to methadone treatment and some specific to prescription opioid-dependent patients receiving buprenorphine/naloxone.
authors: Division of Alcohol and Drug Abuse, McLean Hospital, Belmont, MA 02478, USA. jdreifuss@mclean.harvard.edu
authors: Jessica A
authors: JA
authors: Dreifuss
authors: Margaret L
authors: ML
authors: Griffin
authors: Katherine
authors: K
authors: Frost
authors: Garrett M
authors: GM
authors: Fitzmaurice
authors: Jennifer Sharpe
authors: JS
authors: Potter
authors: David A
authors: DA
authors: Fiellin
authors: Jeffrey
authors: J
authors: Selzer
authors: Mary
authors: M
authors: Hatch-Maillette
authors: Susan C
authors: SC
authors: Sonne
authors: Roger D
authors: RD
authors: Weiss
mesh_terms: D000328:Adult; D000701:Analgesics, Opioid / Q000627:therapeutic use*; D002047:Buprenorphine / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D009270:Naloxone / Q000008:administration & dosage*; D009293:Opioid-Related Disorders / Q000175:diagnosis* / Q000188:drug therapy* / Q000453:epidemiology; D055553:Prescription Drugs / Q000627:therapeutic use*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000701:Analgesics, Opioid; D055553:Prescription Drugs; D009270:Naloxone; D002047:Buprenorphine